Société Générale — M&A Activity 2021

Jun 21, 2021

National Storage Mechanism | Additional information

RNS Number : 5145C

Societe Generale SA

21 June 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	UDG Healthcare plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	€0.05 ordinary shares
Date of dealing	18/06/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	10,265,449	4.07	9,404	0.00
(2) Derivatives (other than options)	0	0.00	6,233,855	2.47
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*10,315,449	*4.09	6,243,259	2.48

* Include the holding of 50,000 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit GBP (Note 5)
Purchase	413	10.47
Purchase	451	10.55
Purchase	1,284	10.46
Purchase	1,303	10.44
Purchase	1,263	10.45
Purchase	1,323	10.43
Purchase	407	10.55
Purchase	445	10.55
Purchase	792	10.54
Purchase	407	10.54
Purchase	57	10.53
Purchase	1,345	10.54
Purchase	1,176	10.53
Sale	341	10.44
Sale	1,911	10.44
Sale	731	10.44
Sale	297	10.57
Sale	5,292	10.57
Sale	47	10.57
Sale	1,237	10.57
Sale	8	10.55
Sale	61	10.54
Sale	57	10.54
Sale	49	10.54
Sale	8	10.56
Sale	5	10.55
Sale	2	10.55
Sale	50	10.55
Sale	2	10.55
Sale	55	10.55
Sale	57	10.54
Sale	61	10.54
Sale	57	10.54
Sale	57	10.54
Sale	37	10.54
Sale	57	10.54
Sale	51	10.54
Sale	20	10.55
Sale	57	10.54
Sale	2	10.55
Sale	57	10.54
Sale	5	10.55
Sale	20	10.55
Sale	30	10.55
Sale	57	10.54
Sale	57	10.54
Sale	61	10.54
Sale	57	10.54
Sale	39	10.55
Sale	52	10.54
Sale	9	10.54
Sale	57	10.56
Sale	35	10.54
Sale	22	10.54
Sale	57	10.54
Sale	57	10.54
Sale	20	10.54
Sale	57	10.54
Sale	57	10.54
Sale	57	10.54
Sale	57	10.54
Sale	58	10.55
Sale	57	10.55
Sale	46	10.54
Sale	11	10.54
Sale	57	10.54
Sale	59	10.54
Sale	57	10.54
Sale	57	10.54
Sale	41	10.55
Sale	57	10.55
Sale	57	10.54
Sale	49	10.56
Sale	59	10.54
Sale	722	10.6
Sale	75	10.56
Sale	2	10.56
Sale	6	10.56
Sale	250	10.57
Sale	746	10.57
Sale	1,330	10.47
Sale	2	10.56
Sale	88	10.56
Sale	5	10.56
Sale	3	10.56
Sale	4	10.56
Sale	82	10.56
Sale	1,152	10.55
Sale	1,305	10.49
Sale	21	10.56
Sale	3	10.56
Sale	4	10.56
Sale	74	10.56
Sale	1,347	10.5
Sale	1	10.56
Sale	572	10.5
Sale	11	10.56
Sale	790	10.58
Sale	490	10.6
Sale	86	10.56
Sale	6	10.56
Sale	11	10.56
Sale	560	10.5
Total Purchases	10,666
Total Sales	21,942

Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit GBP (Note 5)

(b)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to 

which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	21/06/2021
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEPPUBPQUPGUAG